Bob Millham is currently President of Clinical Trial Operations, at Allucent, a global provider of comprehensive drug development solutions. He has more than 20 years of leadership experience across global pharmaceutical, biotech and contract research organizations. Throughout his career he has spearheaded scientific teams, clinical development programs and operations worldwide to drive the success of cancer therapeutics. Highlights of Bob’s career include:
a 17-year career at Pfizer, leading and contributing to the development of compounds against multiple indications of cancer, including lung, breast, colorectal and ovarian.
overseeing drug development activities and opening a pivotal phase 3 clinical trial in metastatic breast cancer while COO of Odonate Therapeutics.
leading the Oncology Center of Excellence, as well as clinical trial management initiatives for a variety of biotech and pharmaceutical clients as senior vice president at Syneos Health.
while in position as vice president of strategic alliances for Caris Life Sciences, growing and developing the organization’s Precision Oncology Alliance network
Bob has authored and co-authored multiple peer-reviewed articles, abstracts, and presentations. He earned a master’s degree in pharmaceutical medicine from Hibernia College in Dublin, Ireland, as well as a master’s degree in microbiology from the University of New Hampshire. He holds a bachelor’s degree in biology from Middlebury College.